Abstract:Background: Clinical practice is guided by guidelines in the era of evidence-based medicine to improve healthcare. The consistency between the strength of recommendations and the underlying quality of evidence in clinical guidelines and its evolution dynamically reflects the status of medical practice in important aspects. This study aimed to evaluate the levels of evidence (LOEs) supporting different classes of recommendations (CORs) in Chinese cardiovascular disease (CVD) guidelines between 2003 and 2021, and changes over time. Methods: Clinical guideline documents on cardiovascular topics issued by leading professional organizations were retrieved in the Databases of SinoMed and Wanfang Med Online from inception to June 2021. All guidelines were screened through abstract and full-text reading, and included if satisfying the pre-specified criteria. 79 Chinese guideline documents on 12 sub-topics including a total of 5195 recommendations and the designated CORs/LOEs, were abstracted. The number of recommendations of Class Ⅰ, Class Ⅱ, Class Ⅲ, LOE A, LOE B, and LOE C were identified for each guideline document. The proportion of CORs, LOEs, and COR-LOE combinations in guidelines and the changes among those with ≥2 versions. Findings: A total of 79 guidelines were included in the analysis. When examining the status of current guidelines, among the 3325 recommendations derived from 59 documents during 2011-2021, 735 recommendations (22.1%) were classified as LOE A, 1280 (38.5%) as LOE B, and 1310 (39.4%) as LOE C. 596 recommendations (17.9%) were characterized as Class Ⅰ-LOE A, accounting for the majority of LOE A recommendations but only one-third of Class I recommendations. Evidence levels varied greatly across different sub-topics and individual guidelines. There are 9 guidelines on 5 sub-topics having ≥2 versions. When analyzing the changes over time, although an increase was observed in the total number of recommendations, the proportion of recommendations designated as Class Ⅰ-LOE A did not significantly improve (19.1% [current] vs 19.0% [prior], p = 0.97). Interpretation: In current Chinese CVD guidelines, the high level of evidence lacks, and its alignment with strong recommendations is deficient. Although it shows moderate improvements in certain major topics (e.g., coronary artery disease, interventional therapy, surgery) in the past two decades, the overall proportion of Class I-LOE A recommendations remains small, suggesting that conduction, and particularly translation, of high-quality studies like RCTs addressing CVDs-related questions are still essential and demanded, especially for areas with less attention. Funding: This study was supported by Beijing Nova Program from Beijing Municipal Science & Technology Commission (Z211100002121063, Z201100006820002); Fundamental Research Funds for the Central Universities (3332022023); National Key R&D Program of China (2020YFC2004705); CAMS Innovation Fund for Medical Sciences (2021-I2M-5-003); National Natural Science Foundation of China (81825003, 91957123, 82270376).

Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023 Edition)

2023 Chinese Expert Consensus on the Impact of COVID-19 on the Management of Cardiovascular Diseases

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic

Chinese Expert Consensus on Microvascular Protection Strategy during Emergency Percutaneous Coronary Intervention Therapy in Patients with ST-elevation Myocardial Infarction

[Chinese expert consensus on antithrombotic therapy of panvascular diseases (2024 edition)]

Chinese patent medicines for coronary microvascular disease: clinical evidence and potential mechanisms

Chinese Expert Consensus on the Risk Assessment and Management of Panvascular Disease Inpatients with Type 2 Diabetes Mellitus (2022 Edition)

Traditional chinese medicine in coronary microvascular disease

Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)

Rethinking on the pathogenesis, diagnosis and treatment of microvascular angina disease based on Chinese and foreign guidelines

Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update

China Expert Consensus on Clinical Application of the Drug-Coated Balloon

Inflammation and coronary microvascular disease: relationship, mechanism and treatment

Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population

Expert Consensus on Nutritional Support for Children with Congenital Heart Disease (2023 Edition)

[Chinese expert consensus on cardiac biomarkers for monitoring and management of cardiovascular toxicity in cancer therapy (2024 edition)]

Coronary microvascular dysfunction and cardiovascular disease: Pathogenesis, associations and treatment strategies

[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)]

Level of evidence supporting the Chinese cardiovascular disease clinical practice guidelines and its evolution in the past two decades

New Understanding and Trends in the Diagnosis and Management of Dry Eye

[Chinese expert consensus on diagnosis and treatment of viral corneal endotheliitis (2023)]